Nextgen Share Discussion Threads

[mypension] 22/2/2012 12:52

Many thanks Stephanie M

[stephanie_m] 22/2/2012 12:42

Duplicated - Deleted

s

[stephanie_m] 22/2/2012 12:42

As requested:



s

[markmewerds] 22/2/2012 10:37

Looks like 5 buys 3 sells bigger trades are buys though.

[mypension] 22/2/2012 10:31

Anyone with Level 2 - are those millions traded today buys or sells?

[the_doctor] 12/2/2012 15:19

sadly some here listened to the rampers rather than the thought-out views posted by myself from Apr last year

[stephanie_m] 11/2/2012 02:50

Late reported,presume roll over, trade of 218 Million shares. The privelege cost the investor a fee of £3052.

s

[bobby.ifa] 31/1/2012 09:07

Good luck SM, I've written these off. Once they get to .3p I'm out.(If they ever get there, that is).

[stephanie_m] 30/1/2012 22:44

Added more!!.

s

[stephanie_m] 19/1/2012 08:26

Going to make a further speculative investment in NGG.

A takeover perhaps?

s

[the_doctor] 14/12/2011 17:02

'Ann Arbor, Michigan, US, and London, UK, 6 December 2011 - NextGen Group plc (AIM:NGG) is pleased to announce that its US-subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has appointed Steve Zolnay as Vice President of Business Development for North America.'

where did their last guy go?? ;o)

[bobby.ifa] 14/12/2011 16:47

Look at all warrants, once exercised this company will be heavily diluted, killing the value for any current share-holders.

[bobby.ifa] 02/12/2011 11:57

Not sure how to read this news, I don't like the warning about the lack of protection afforded to us shareholders. Almost a precurser to imminent bad news.

[moggey07] 14/11/2011 16:33

will be raising money q1 2012

[bobby.ifa] 04/11/2011 14:00

Looks like one of duff investments eeking out its final year before bankruptcy.Doh!
Arrangement fee is outrageous.

[dubois] 04/11/2011 13:11

wow thats some payment. It costs them £123500 EU just to borrow the money and they still have to pay interest on top. Good game!

[the_doctor] 12/9/2011 18:09

Is this not due to raise cash very soon??

not a deramp, I'm just intrigued.
They may be able to get profitable on what they have, but unlike PRM, no larger deal prospects.

[awja] 25/8/2011 06:35

6,994,542,570 people in the world.
About 1 share each :-)

[34simon] 24/8/2011 06:59

7 billion shares in issue !

[bobby.ifa] 10/8/2011 08:44

Blimey, its been quiet on here, no post for 5 weeks. Wakey wakey, up 15%, but for how long?

[stephanie_m] 03/7/2011 21:09

Probably

s

[the_doctor] 03/7/2011 20:13

What the author really means is 'three microcap stocks that they were able to ramp in the extreme and generate enough buyer interest for ludicrous moves... and would like to ramp some more'

[stephanie_m] 03/7/2011 17:21

July 2011's Penny Shares to Watch...

This month's penny shares to watch:

Why biotech will command the headlines this year...

Sareum Holdings (SAR), Valirx (VAL), Nextgen (NGG)

Three small cap 'internet cops' waging war on cybercrime...

Coreroc (CORO), Datatec (DTC), Digital Barriers (DGB), NCC Group (NCC)

To read more about this month's penny share tips take a no obligation trial now and INSTANTLY DOWNLOAD the latest issue PLUS get 3 free special reports!
Looking to invest in penny shares? Keep reading to discover my ideas for the coming month...



Why biotech will command the headlines this year
(This article first appeared in Penny Sleuth in June 2011. Penny Sleuth is an unregulated free e-letter written by Tom Bulford and published by MoneyWeek Limited)

This year has seen the dramatic revival of a small sector that has long been written off by most investors.

Until now, biotech has been the stuff of nightmares. The medical terminology is baffling. The process of medical discovery is long and expensive. But above all the vast sums of money poured into biotech have paid glorious salaries for chemists and biologists – but precious little to outside investors.

But a sea change in the industry could change all that. For years big pharma has lead the way in bringing blockbuster drugs to market. But they can't do it any longer. Racked by costs and under threat from generic drug developers, the big pharmaceuticals are stepping back from research.

And that opens the door for biotechs. Over the next few years I think it is likely to be biotech stocks that command the headlines in this industry. And the advances underway in biotech could prove hugely lucrative for penny investors...